Prophylactic effect of lactobacilli and bifidobacteria probiotic strains on experimental bacterial vaginitis

Keywords: Lactobacillus; Bifidobacterium; Staphylococcus; microbiota; vagina; gut; mice


The objective of the study was determining the prophylactic effect of Lactobacillus casei IMV B-7280, L. acidophilus IMV B-7279, L. delbrueckii subsp. bulgaricus IMV B-7281, Bifidobacterium animalis VKL and B. animalis VKB probiotic strains on experimental vaginitis in BALB/c mice induced by Staphylococcus aureus 8325-4. The infection with S. aureus 8325-4 caused an imbalance of microbiota in the vagina and intestine, as evidenced by an increase in the number of opportunistic microorganisms and a decrease in the amount of lactobacilli and bifidobacteria. L. casei IMV B-7280, B. animalis VKL and B. animalis VKB probiotic strains altered the microbiota spectrum of the vagina and intestine of Staphylococcus-infected mice: the amount of Lactobacillus and bifidobacteria increased with the reduction of the number of opportunistic microorganisms. Also under the influence of these strains, the normalization of the microbiota spectrum typical for vagina and intestine was observed in different periods of observation – in the intestines of mice the number of coliform bacteria increased, the number of microscopic fungi, streptococci and staphylococci decreased; in the vagina, the number of coliform bacteria and microscopic fungi decreased, the number of streptococci normalized. Rapid elimination of S. aureus 8325-4 from the vagina and prevention of the spread of infection to the intestine were observed after use of probiotics. Preventive effect of L. acidophilus IMV B-7279 and L. delbrueckii subsp. bulgaricus IMV B-7281 for bacterial vaginitis in mice was less effective. So, the target probiotic strains L. casei IMV B-7280, B. animalis VKL and B. animalis VKB are promising for the creation of highly effective novel probiotic drugs that can be used for directed prevention of infectious and inflammatory diseases of the genitourinary system caused by pathogenic and opportunistic microorganisms.


Babenko, L. P., Lazarenko, L. M., Demchenko, O. A., Konarbaeva, Z. K., & Spivak, M. J. (2015). Antibacterial activity of Lactobacillus casei IMV B-7280 in cases of experimental urogenital staphylococcal infection. Biotechnologia Acta, 8(3), 95–103.

Barbés, C., & Boris, S. (1999). Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS Patient Care and STDs, 13(12), 747–751.

Brown, D. F., & Perry, S. F. (1992). Methods used in the United Kingdom for the culture of micro-organisms from blood. Journal of Clinical Pathology, 45(6), 468–474.

Brubaker, L., & Wolfe, A. J. (2017). The female urinary microbiota / microbiome: Clinical and research implications. Rambam Maimonides Medical Journal, 8(2), e0015.

Brubaker, L., & Wolfe, A. J. (2017). The female urinary microbiota, urinary health and common urinary disorders. Annals of Translational Medicine, 5, 34–34.

Cianci, A., Cicinelli, E., De Leo, V., Fruzzetti, F., Massaro, M. G., Bulfoni, A., & Perino, A. (2018). Observational prospective study on Lactobacillus plantarum P 17630 in the prevention of vaginal infections, during and after systemic antibiotic therapy or in women with recurrent vaginal or genitourinary infections. Journal of Obstetrics and Gynaecology, 38(5), 693–696.

De Jongh, D. S., Loftis, J. W., Green, G. S., Shively, J. A., & Minckler, T. M. (1968). Postmortem bacteriology: A practical method for routine use. American Journal of Clinical Pathology, 49(3), 424–428.

Frey Tirri, B. (2011). Antimicrobial topical agents used in the vagina. Current Problems in Dermatology, 40, 36–47.

Grin, P. M., Kowalewska, P. M., Alhazzan, W., & Fox-Robichaud, A. E. (2013). Lactobacillus for preventing recurrent urinary tract infections in women: Meta-analysis. Canadian Journal of Urology, 20(1), 6607–6614.

Hay, P. E. (2004). Bacterial vaginosis and miscarriage. Current Opinion in Infectious Diseases, 17(1), 41–44.

Kenyon, C. R., & Osbak, K. (2014). Recent progress in understanding the epidemiology of bacterial vaginosis. Current Opinion in Obstetrics and Gynecology, 26(6), 448–454.

Lazarenko, L., Babenko, L., Mokrozub, V., Voronkevich, M., Loseva, D., Sichel, L., & Spivak, M. (2017). The effect of lactic acid bacteria and bifidobacteria on the number of natural killer cells in normal conditions and in cases of intravaginal staphylococcosis in mice. Research Bulletin of the National Technical University of Ukraine “Kyiv Politechnic Institute”, 3, 48–56.

Lazarenko, L., Babenko, L., Sichel, L., Pidgorskyi, V., Mokrozub, V., Voronkova, O., & Spivak, M. (2012). Antagonistic action of lactobacilli and bifidobacteria in relation to Staphylococcus aureus and their influence on the immune response in cases of intravaginal staphylococcosis in mice. Probiotics and Antimicrobial Proteins, 4(2), 78–89.

MacPhee, R. A., Miller, W. L., Gloor, G. B., McCormick, J. K., Hammond, J.-A., Burton, J. P., & Reid, G. (2013). Influence of the vaginal microbiota on toxic shock syndrome toxin 1 production by Staphylococcus aureus. Applied and Environmental Microbiology, 79(6), 1835–1842.

Martin, H. L., Richardson, B. A., Nyange, P. M., Lavreys, L., Hillier, S. L., Chohan, B., & Kreiss, J. (1999). Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. The Journal of Infectious Diseases, 180(6), 1863–1868.

McMillan, A., Rulisa, S., Sumarah, M., Macklaim, J. M., Renaud, J., Bisanz, J. E., & Reid, G. (2015). A multi-platform metabolomics approach identifies highly specific biomarkers of bacterial diversity in the vagina of pregnant and non-pregnant women. Scientific Reports, 5(1), 4965–4975.

Mokrozub, V. V., Lazarenko, L. M., Sichel, L. M., Babenko, L. P., Lytvyn, P. M., Demchenko, O. M., & Spivak, M. Y. (2015). The role of beneficial bacteria wall elasticity in regulating innate immune response. EPMA Journal, 6(1), 13–22.

Mumtaz, S., Ahmad, M., Aftab, I., Akhtar, N., Ul Hassan, M., & Hamid, A. (2008). Aerobic vaginal pathogens and their sensitivity pattern. Journal of Ayub Medical College Abbottabad, 20(1), 113–117.

Murina, F., Graziottin, A., Vicariotto, F., & De Seta, F. (2014). Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis? Journal of Clinical Gastroenterology, 48, S102–S105.

Niwayama, G. (1971). Postmortem blood microbiology using sterile autopsy technique. The Tohoku Journal of Experimental Medicine, 105(3), 247–256.

Pascual, L. M., Daniele, M. B., Ruiz, F., Giordano, W., Pájaro, C., & Barberis, L. (2008). Lactobacillus rhamnosus L60, a potential probiotic isolated from the human vagina. The Journal of General and Applied Microbiology, 54(3), 141–148.

Podgorskij, B. C., Ljaskovskij, T. M., Kovalenko, N. K., & Oleshhenko, L. T. (2006). Izuchenie vaginal'noj i kishechnoj mikrobіoty zhenshhin v predrodovom periode i ee korrekcija pri disbioticheskih narushenijah [Study of the vaginal and intestinal microbiota of women in the prenatal period and its correction for dysbiotic disorders]. Microbiological Journal, 68(2), 92–104 (in Russian).

Recine, N., Palma, E., Domenici, L., Giorgini, M., Imperiale, L., Sassu, C., & Benedetti Panici, P. (2015). Restoring vaginal microbiota: Biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Archives of Gynecology and Obstetrics, 293(1), 101–107.

Reid, G. (2001). Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunology and Medical Microbiology, 32(1), 37–41.

Reid, G. (2017). Is bacterial vaginosis a disease? Applied Microbiology and Biotechnology, 102(2), 553–558.

Reznіkov, O. (2001) Problemy etyky pry provedenni eksperymentalnykh medychnykh i biolohichnykh doslidzhen na tvarynakh [Problems of ethics during conducting of experimental medical and biological researches on animals]. Visnyk of the National Academy of Sciences of Ukraine, 1(1), 5–7 (in Ukrainian).

Schwebke, J. R. (2003). Gynecologic consequences of bacterial vaginosis. Obstetrics and gynecology clinics of North America, 30(4), 685–694.

Thomas-White, K. J., Hilt, E. E., Fok, C., Pearce, M. M., Mueller, E. R., Kliethermes, S., & Wolfe, A. J. (2015). Incontinence medication response relates to the female urinary microbiota. International Urogynecology Journal, 27(5), 723–733.

Verstraelen, H. (2008). Cutting edge: The vaginal microflora and bacterial vaginosis. Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie, 70(3), 147–174.

Wood, L. N., & Anger, J. T. (2014). Urinary incontinence in women. British Medical Journal, 349, g4531–g4531.